Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Innovent Biologics Inc.
Headquarters: Suzhou, China
Website: http://cn.innoventbio.com/en/...
Year Founded: 2011
Status: Public
Industry Sector: HealthTechnology
CEO: De Chao Yu, PhD
Number Of Employees: N/A
Enterprise Value: $6,980,635,307
PE Ratio: -735.67
Exchange/Ticker 1: HKEX:1801
Exchange/Ticker 2: N/A
Latest Market Cap: $9,731,470,704
BioCentury | Mar 29, 2025
Product Development
Bispecifics for I&I: Bypassing combination complexity
At least 30 companies have bispecific antibodies in development for autoimmune and inflammatory diseases
BioCentury | Jan 7, 2025
Deals
Irish sale from Wuxi Biologics, Roche looks to Innovent for ADC
BioCentury’s Deals Report: Wuxi Biologics, Hutchmed in asset sales and more
BioCentury | Nov 19, 2024
Deals
More bispecific deals in China: Aclaris/Biosion, Ouro/Keymed, Avenzo/VelaVigo
BioCentury’s Deals Report also includes GSK’s agreement with Flagship-backed Vesalius in Parkinson’s disease, and more
BioCentury | Oct 29, 2024
Product Development
Market reaction to Intellia data suggests perfection remains bar for gene editing
Clinical Report: Celldex advances in a second urticaria type, Eledon’s mAb helps Type I diabetes patients become insulin-independent, and more
BioCentury | Oct 24, 2024
Data Byte
New modalities flood the EGFR pipeline
Bispecifics, ADCs and more compete to become the next-generation of EGFR-targeting agents
BioCentury | Oct 15, 2024
Deals
Three new partnerships that could be worth over $1B
Deals report: Astellas-AviadoBio in CNS gene therapy deal, Merck-Mestag to identify inflammatory targets, Eli Lilly-KeyBioscience tackling obesity
BioCentury | Jul 31, 2024
Management Tracks
Min Liu succeeds Yiping Li as CEO of JW
Plus: John Chin to retire as CBO from Antengene, and updates from ADARx, bit bio and Santhera
BioCentury | Jul 29, 2024
Deals
Deals Report: GSK is latest pharma to draw on Flagship portfolio
Plus: Day One’s ex-U.S. deal with Ipsen; Novartis taps Dren Bio’s oncology platform; BI buys Avalon-backed Nerio; and Collegium’s ADHD takeout
BioCentury | Jul 23, 2024
Product Development
Clinical Report: Ionis’ therapy for Angelman syndrome heading for Phase III
Plus: Data from Innovent, Agenus, Merck, Bayer and Orion
BioCentury | Jul 8, 2024
Deals
Deals report: Lilly acquires Morphic, GSK gets full rights for mRNA vaccines from CureVac
Plus: Iaso gets full rights to Fucaso from Innovent, and updates from Genexine, EPD, Pentixapharm and Glycotope
Items per page:
1 - 10 of 233